These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25826393)

  • 1. Pik3ip1 modulates cardiac hypertrophy by inhibiting PI3K pathway.
    Song HK; Kim J; Lee JS; Nho KJ; Jeong HC; Kim J; Ahn Y; Park WJ; Kim DH
    PLoS One; 2015; 10(3):e0122251. PubMed ID: 25826393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuating PI3K/Akt- mTOR pathway reduces dihydrosphingosine 1 phosphate mediated collagen synthesis and hypertrophy in primary cardiac cells.
    Magaye RR; Savira F; Hua Y; Xiong X; Huang L; Reid C; Flynn BL; Kaye D; Liew D; Wang BH
    Int J Biochem Cell Biol; 2021 May; 134():105952. PubMed ID: 33609744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HTR2A promotes the development of cardiac hypertrophy by activating PI3K-PDK1-AKT-mTOR signaling.
    Gao W; Guo N; Zhao S; Chen Z; Zhang W; Yan F; Liao H; Chi K
    Cell Stress Chaperones; 2020 Nov; 25(6):899-908. PubMed ID: 32519137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboxypeptidase A4 promotes cardiomyocyte hypertrophy through activating PI3K-AKT-mTOR signaling.
    Gao W; Guo N; Zhao S; Chen Z; Zhang W; Yan F; Liao H; Chi K
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32347291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin prevents thyroid hormone-induced cardiac hypertrophy.
    Kuzman JA; O'Connell TD; Gerdes AM
    Endocrinology; 2007 Jul; 148(7):3477-84. PubMed ID: 17395699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling.
    Ai W; Zhang Y; Tang QZ; Yan L; Bian ZY; Liu C; Huang H; Bai X; Yin L; Li H
    J Cell Biochem; 2010 Aug; 110(5):1111-22. PubMed ID: 20564207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cardiac myocyte-restricted Lin28/let-7 regulatory axis promotes hypoxia-mediated apoptosis by inducing the AKT signaling suppressor PIK3IP1.
    Joshi S; Wei J; Bishopric NH
    Biochim Biophys Acta; 2016 Feb; 1862(2):240-51. PubMed ID: 26655604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indoleamine 2,3-Dioxygenase 1 (IDO1) Promotes Cardiac Hypertrophy via a PI3K-AKT-mTOR-Dependent Mechanism.
    Liu Y; Li S; Gao Z; Li S; Tan Q; Li Y; Wang D; Wang Q
    Cardiovasc Toxicol; 2021 Aug; 21(8):655-668. PubMed ID: 34021461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy.
    Kemi OJ; Ceci M; Wisloff U; Grimaldi S; Gallo P; Smith GL; Condorelli G; Ellingsen O
    J Cell Physiol; 2008 Feb; 214(2):316-21. PubMed ID: 17941081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. H-Ras Isoform Mediates Protection Against Pressure Overload-Induced Cardiac Dysfunction in Part Through Activation of AKT.
    Matsuda T; Jeong JI; Ikeda S; Yamamoto T; Gao S; Babu GJ; Zhai P; Del Re DP
    Circ Heart Fail; 2017 Feb; 10(2):. PubMed ID: 28193718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K.
    Weeks KL; Tham YK; Yildiz SG; Alexander Y; Donner DG; Kiriazis H; Harmawan CA; Hsu A; Bernardo BC; Matsumoto A; DePinho RA; Abel ED; Woodcock EA; McMullen JR
    Am J Physiol Heart Circ Physiol; 2021 Apr; 320(4):H1470-H1485. PubMed ID: 33577435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PICOT inhibits cardiac hypertrophy and enhances ventricular function and cardiomyocyte contractility.
    Jeong D; Cha H; Kim E; Kang M; Yang DK; Kim JM; Yoon PO; Oh JG; Bernecker OY; Sakata S; Le TT; Cui L; Lee YH; Kim DH; Woo SH; Liao R; Hajjar RJ; Park WJ
    Circ Res; 2006 Aug; 99(3):307-14. PubMed ID: 16809552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldehyde dehydrogenase 2 deficiency blunts compensatory cardiac hypertrophy through modulating Akt phosphorylation early after transverse aorta constriction in mice.
    Xia G; Fan F; Liu M; Wang S; Wu J; Shen C; Han S; Wang C; Jia J; Zou Y; Hu K; Ge J; Sun A
    Biochim Biophys Acta; 2016 Sep; 1862(9):1587-93. PubMed ID: 27239698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac Stim1 Silencing Impairs Adaptive Hypertrophy and Promotes Heart Failure Through Inactivation of mTORC2/Akt Signaling.
    Bénard L; Oh JG; Cacheux M; Lee A; Nonnenmacher M; Matasic DS; Kohlbrenner E; Kho C; Pavoine C; Hajjar RJ; Hulot JS
    Circulation; 2016 Apr; 133(15):1458-71; discussion 1471. PubMed ID: 26936863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of cardiac hypertrophy by inhibiting both mTOR and NFkappaB activation in vivo.
    Ha T; Li Y; Gao X; McMullen JR; Shioi T; Izumo S; Kelley JL; Zhao A; Haddad GE; Williams DL; Browder IW; Kao RL; Li C
    Free Radic Biol Med; 2005 Dec; 39(12):1570-80. PubMed ID: 16298682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focal adhesion kinase governs cardiac concentric hypertrophic growth by activating the AKT and mTOR pathways.
    Clemente CF; Xavier-Neto J; Dalla Costa AP; Consonni SR; Antunes JE; Rocco SA; Pereira MB; Judice CC; Strauss B; Joazeiro PP; Matos-Souza JR; Franchini KG
    J Mol Cell Cardiol; 2012 Feb; 52(2):493-501. PubMed ID: 22056317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lupeol protects against cardiac hypertrophy via TLR4-PI3K-Akt-NF-κB pathways.
    Li D; Guo YY; Cen XF; Qiu HL; Chen S; Zeng XF; Zeng Q; Xu M; Tang QZ
    Acta Pharmacol Sin; 2022 Aug; 43(8):1989-2002. PubMed ID: 34916609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K is negatively regulated by PIK3IP1, a novel p110 interacting protein.
    Zhu Z; He X; Johnson C; Stoops J; Eaker AE; Stoffer DS; Bell A; Zarnegar R; DeFrances MC
    Biochem Biophys Res Commun; 2007 Jun; 358(1):66-72. PubMed ID: 17475214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase Cbeta2 in the regulation of physiologic developmental hypertrophy and heart function.
    Rigor DL; Bodyak N; Bae S; Choi JH; Zhang L; Ter-Ovanesyan D; He Z; McMullen JR; Shioi T; Izumo S; King GL; Kang PM
    Am J Physiol Heart Circ Physiol; 2009 Mar; 296(3):H566-72. PubMed ID: 19122165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.
    Marin TM; Clemente CF; Santos AM; Picardi PK; Pascoal VD; Lopes-Cendes I; Saad MJ; Franchini KG
    Circ Res; 2008 Oct; 103(8):813-24. PubMed ID: 18757826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.